← Leaderboards
Tracy W Liu
West Virginia University
$1,505,656
Attributed
$1,957,107
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $932K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,957,107 · 3
By mechanism
P20$1,279,931 · 2
R01$677,176 · 1
Top collaborators
- Jonathan F Lovell1 shared
- Gal Shafirstein1 shared
Others in their field
Other Emerging Leaders on “Immunotherapy”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,653,178
- Leonard Freedman · Leidos Biomedical Research, Inc.$66,640,671
- Leonard Freedmand · Leidos Biomedical Research, Inc.$54,755,085
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$28,983,611
Research focus
ImmunotherapyMolecularTumor MicroenvironmentResponseMyeloid CellsNadph OxidaseNeurodegenerative DisordersImmune SystemInhibitorEnzymesGeneticMonocyteHistologicMyeloid-Derived Suppressor CellsBlood SpecimenAnimalsCellsCheckpoint TherapyAdjuvantImmuneCell CommunicationImmunosuppressionBloodDisease Progression
Grant awards (6)
Interstitial Chemophototherapy as an Intervention in Locally Advanced Pancreatic Cancer$677,176
R01 · FY2025 · CA
Targeting ROS enzymes in immunosuppressive myeloid cells to enhance immunotherapy$254,788
P20 · FY2025 · GM · contact PI
Targeting ROS enzymes in immunosuppressive myeloid cells to enhance immunotherapy$260,435
P20 · FY2024 · GM · contact PI
Targeting ROS enzymes in immunosuppressive myeloid cells to enhance immunotherapy$237,783
P20 · FY2023 · GM · contact PI
Targeting ROS enzymes in myeloid-derived suppressor cell to enhance immunotherapy$263,733
P20 · FY2022 · GM · contact PI
Targeting ROS enzymes in myeloid-derived suppressor cell to enhance immunotherapy$263,192
P20 · FY2021 · GM · contact PI